Ascendis Pharma A/S (ASND)

NASD · Healthcare · Biotechnology · Denmark

Ascendis Pharma A/S is a large cap company (market value between $10 billion and $200 billion) in the Biotechnology industry.

Intrinsic value, DCF valuation, financial health and value investing analysis for the Ascendis Pharma A/S stock.

Our verdict on ASND

Overvalued: intrinsic value $86.66 per share, market price $271.19, margin of safety -213.0% (as of 2026-11-17).

A 4.2x revenue multiple, discounted for its losses, values the shares at $86.66; the price of $271.19 is 213% above that value.

ETFs with the most weight in ASND

17 more funds hold it; the full list is part of the paid plan.

More on ASND

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than ASND in Biotechnology

70 more in this industry show a wider margin of safety.

Is ASND undervalued or overvalued?

ASND is overvalued (as of the 2026-11-17 close). A 4.2x revenue multiple, discounted for its losses, values the shares at $86.66; the price of $271.19 is 213% above that value.

What is the intrinsic value of ASND?

$86.66 per share (as of the 2026-11-17 close), against a market price of $271.19. That is a margin of safety of -213.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.